CDK4 and neoplasm: However, the possible radiosensitizing effects of the cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) inhibitor palbociclib are not limited to tumor cells alone, but can also affect healthy cells.